JP2022549169A5 - - Google Patents

Info

Publication number
JP2022549169A5
JP2022549169A5 JP2022517438A JP2022517438A JP2022549169A5 JP 2022549169 A5 JP2022549169 A5 JP 2022549169A5 JP 2022517438 A JP2022517438 A JP 2022517438A JP 2022517438 A JP2022517438 A JP 2022517438A JP 2022549169 A5 JP2022549169 A5 JP 2022549169A5
Authority
JP
Japan
Application number
JP2022517438A
Other languages
Japanese (ja)
Other versions
JP7652434B2 (ja
JPWO2021055705A5 (https=
JP2022549169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051430 external-priority patent/WO2021055705A1/en
Publication of JP2022549169A publication Critical patent/JP2022549169A/ja
Publication of JP2022549169A5 publication Critical patent/JP2022549169A5/ja
Publication of JPWO2021055705A5 publication Critical patent/JPWO2021055705A5/ja
Priority to JP2025036781A priority Critical patent/JP2025094953A/ja
Application granted granted Critical
Publication of JP7652434B2 publication Critical patent/JP7652434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517438A 2019-09-18 2020-09-18 がん治療のためのビアミノキノリンとナノ製剤 Active JP7652434B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036781A JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902156P 2019-09-18 2019-09-18
US62/902,156 2019-09-18
PCT/US2020/051430 WO2021055705A1 (en) 2019-09-18 2020-09-18 Biaminoquinolines and nanoformulations for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036781A Division JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Publications (4)

Publication Number Publication Date
JP2022549169A JP2022549169A (ja) 2022-11-24
JP2022549169A5 true JP2022549169A5 (https=) 2023-09-25
JPWO2021055705A5 JPWO2021055705A5 (https=) 2023-09-25
JP7652434B2 JP7652434B2 (ja) 2025-03-27

Family

ID=74884705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517438A Active JP7652434B2 (ja) 2019-09-18 2020-09-18 がん治療のためのビアミノキノリンとナノ製剤
JP2025036781A Pending JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036781A Pending JP2025094953A (ja) 2019-09-18 2025-03-07 がん治療のためのビアミノキノリンとナノ製剤

Country Status (6)

Country Link
US (1) US20230348419A1 (https=)
EP (1) EP4031543A4 (https=)
JP (2) JP7652434B2 (https=)
CN (2) CN115023418B (https=)
CA (1) CA3154678A1 (https=)
WO (1) WO2021055705A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
EP4031543A4 (en) * 2019-09-18 2023-09-27 The Regents Of The University Of California Biaminoquinolines and nanoformulations for cancer treatment
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114948938B (zh) * 2022-02-22 2023-08-11 江苏省中医院 白术内酯i在制备预防和/或治疗宫颈癌的药物中的用途
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法
CN116059172B (zh) * 2023-02-01 2025-05-13 中山大学附属第八医院(深圳福田) 一种纳米递药系统及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613322A4 (en) * 2003-04-11 2008-08-13 Taigen Biotechnology Co Ltd AMINOQUINOLINE COMPOUNDS
US20130011448A1 (en) * 2010-03-16 2013-01-10 Ge Healthcare Bio-Sciences Ab System for improved delivery of gene modulating compounds
CN103687853B (zh) * 2011-04-29 2017-12-08 宾夕法尼亚大学托管会 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途
WO2015068142A2 (en) * 2013-11-11 2015-05-14 Cellworks Group, Inc. Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder
ES2881048T3 (es) * 2014-08-08 2021-11-26 Univ Pennsylvania Bisaminoquinolinas asimétricas y bisaminoquinolinas con enlazadores variados como inhibidores de la autofagia para el cáncer y otras terapias
US10774047B2 (en) * 2015-04-17 2020-09-15 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
US20180280372A1 (en) * 2016-11-22 2018-10-04 Washington University Compositions and methods for inhibiting autophagy and contraception
EP4031543A4 (en) * 2019-09-18 2023-09-27 The Regents Of The University Of California Biaminoquinolines and nanoformulations for cancer treatment

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022549169A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)